Answers are grounded in this paper and cite their sources.
Observational study identifies airway wall thickness as a key biomarker of disease activity in COPD, suggesting new monitoring strategies.
Extract Chronic obstructive pulmonary disease (COPD) is characterised by heterogeneous airway inflammation and a variable clinical course [1]. Active airway inflammation can drive progressive structural and functional damage [1]. The concept of disease activity has therefore emerged as a framework to monitor disease progression and stability and to define attainable therapy targets [2]. However, quantifiable markers of disease activity beyond symptom burden, exacerbations, or lung function decline remain limited, particularly CT biomarkers of structural airway changes that are applicable across the full spectrum of smoking-related airway disease, including smokers at risk.
No takes yet. Share an insight, caveat, or question.
Abdo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: